CompletedInterventionalPhase 3Last updated Aug 21, 2018

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Overview

ClinicalTrials.gov ID: NCT02196506
Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY
Brief Summary: The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Jul 2014
Primary Completion Date: Apr 2016Actual
Completion Date: May 2016Actual

Study Record Dates

First Submitted: Jul 18, 2014
First Submitted that Met QC Criteria: Jul 18, 2014
First Posted: Jul 22, 2014Estimated
Last Update Submitted that Met QC Criteria: Aug 17, 2018
Last Update Posted: Aug 21, 2018Actual
Last Verified: Aug 2018

NCT02012218Completed

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

NCT02013531Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

NCT03487198Terminated

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

NCT03538691Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT02013609Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

NCT01360645Completed

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)